AustralieFrV1, PascalFrancis, Curation, bibRecord, 004404

Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Identifieur interne : 004404 ( PascalFrancis/Curation ); précédent : 004403; suivant : 004405

Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Auteurs : Elise A. Olsen [États-Unis] ; Sean Whittaker [Royaume-Uni] ; Youn H. Kim [États-Unis] ; Madeleine Duvic [États-Unis] ; H. Miles Prince [Australie] ; Stuart R. Lessin [États-Unis] ; Gary S. Wood [États-Unis] ; Rein Willemze [Pays-Bas] ; Marie-France Demierre [États-Unis] ; Nicola Pimpinelli [Italie] ; Maria Grazia Bernengo [Italie] ; Pablo L. Ortiz-Romero [Espagne] ; Martine Bagot [France] ; Teresa Estrach [Espagne] ; Joan Guitart [France] ; Robert Knobler ; José Antonio Sanches ; Keiji Iwatsuki ; Makoto Sugaya ; Reinhard Dummer ; Mark Pittelkow ; Richard Hoppe [États-Unis] ; Sareeta Parker ; Larisa Geskin [États-Unis] ; Lauren Pinter-Brown [États-Unis] ; Michael Girardi ; Günter Burg ; Annamari Ranki ; Maartan Vermeer [Pays-Bas] ; Steven Horwitz ; Peter Heald ; Steve Rosen [États-Unis] ; Lorenzo Cerroni ; Brigette Dreno [France] ; Eric C. Vonderheid

Source :

Journal of clinical oncology [ 0732-183X ] ; 2011.

RBID : Pascal:11-0307579

Descripteurs français

Pascal (Inist)
- Mycosis fongoïde, Consensus, International, Syndrome de Sezary, Peau, Etats-Unis, Cancer, Force, Europe, Tumeur maligne, Recherche, Traitement, Cancérologie, Chronique, Lymphome T cutané, Hémopathie maligne lymphoïde, Hémopathie lymphoïde T.
Wicri :
- topic : Cancer, Recherche.

English descriptors

KwdEn :
- Cancer, Cancerology, Chronic, Consensus, Cutaneous T cell lymphoma, Europe, Force, International, Lymphoid neoplasm, Malignant tumor, Mycosis fungoides, Research, Sezary syndrome, Skin, T cell neoplasm, Treatment, United States.

Abstract

Mycosis fungoides (MF) and Sezary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS.

A01	`01`	`1`		`@0 0732-183X`
A03		`1`		`@0 J. clin. oncol.`
A05				`@2 29`
A06				`@2 18`
A08	`01`	`1`	`ENG`	`@1 Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer`
A11	`01`	`1`		`@1 OLSEN (Elise A.)`
A11	`02`	`1`		`@1 WHITTAKER (Sean)`
A11	`03`	`1`		`@1 KIM (Youn H.)`
A11	`04`	`1`		`@1 DUVIC (Madeleine)`
A11	`05`	`1`		`@1 MILES PRINCE (H.)`
A11	`06`	`1`		`@1 LESSIN (Stuart R.)`
A11	`07`	`1`		`@1 WOOD (Gary S.)`
A11	`08`	`1`		`@1 WILLEMZE (Rein)`
A11	`09`	`1`		`@1 DEMIERRE (Marie-France)`
A11	`10`	`1`		`@1 PIMPINELLI (Nicola)`
A11	`11`	`1`		`@1 GRAZIA BERNENGO (Maria)`
A11	`12`	`1`		`@1 ORTIZ-ROMERO (Pablo L.)`
A11	`13`	`1`		`@1 BAGOT (Martine)`
A11	`14`	`1`		`@1 ESTRACH (Teresa)`
A11	`15`	`1`		`@1 GUITART (Joan)`
A11	`16`	`1`		`@1 KNOBLER (Robert)`
A11	`17`	`1`		`@1 ANTONIO SANCHES (José)`
A11	`18`	`1`		`@1 IWATSUKI (Keiji)`
A11	`19`	`1`		`@1 SUGAYA (Makoto)`
A11	`20`	`1`		`@1 DUMMER (Reinhard)`
A11	`21`	`1`		`@1 PITTELKOW (Mark)`
A11	`22`	`1`		`@1 HOPPE (Richard)`
A11	`23`	`1`		`@1 PARKER (Sareeta)`
A11	`24`	`1`		`@1 GESKIN (Larisa)`
A11	`25`	`1`		`@1 PINTER-BROWN (Lauren)`
A11	`26`	`1`		`@1 GIRARDI (Michael)`
A11	`27`	`1`		`@1 BURG (Günter)`
A11	`28`	`1`		`@1 RANKI (Annamari)`
A11	`29`	`1`		`@1 VERMEER (Maartan)`
A11	`30`	`1`		`@1 HORWITZ (Steven)`
A11	`31`	`1`		`@1 HEALD (Peter)`
A11	`32`	`1`		`@1 ROSEN (Steve)`
A11	`33`	`1`		`@1 CERRONI (Lorenzo)`
A11	`34`	`1`		`@1 DRENO (Brigette)`
A11	`35`	`1`		`@1 VONDERHEID (Eric C.)`
A14	`01`			`@1 Duke University Medical Center @2 Durham, NC @3 USA @Z 1 aut.`
A14	`02`			`@1 St John's Institute of Dermatology, Guy's and St Thomas' National Health Services Foundation Trust, Kings College London @3 GBR @Z 2 aut.`
A14	`03`			`@1 Stanford Cancer Center @3 USA @Z 3 aut.`
A14	`04`			`@1 Stanford University @2 Stanford @3 USA @Z 22 aut.`
A14	`05`			`@1 University of California at Los Angeles @2 Los Angeles, CA @3 USA @Z 25 aut.`
A14	`06`			`@1 University of Texas MD Anderson Cancer Center @2 Houston, TX @3 USA @Z 4 aut.`
A14	`07`			`@1 Peter MacCallum Cancer Centre and University of Melbourne @2 Melbourne @3 AUS @Z 5 aut.`
A14	`08`			`@1 Fox Chase Cancer Center @2 Philadelphia @3 USA @Z 6 aut.`
A14	`09`			`@1 University of Pittsburgh School of Medicine @2 Pittsburgh, PA @3 USA @Z 24 aut.`
A14	`10`			`@1 University of Wisconsin and VA Medical Center @2 Madison, WI @3 USA @Z 7 aut.`
A14	`11`			`@1 Leiden University Medical Center @2 Leiden @3 NLD @Z 8 aut. @Z 29 aut.`
A14	`12`			`@1 Boston University @2 Boston, MA @3 USA @Z 9 aut.`
A14	`13`			`@1 University of Florence Medical School @2 Florence @3 ITA @Z 10 aut.`
A14	`14`			`@1 Turin University @2 Turin @3 ITA @Z 11 aut.`
A14	`15`			`@1 Universidad Complutense @2 Madrid @3 ESP @Z 12 aut.`
A14	`16`			`@1 Hospital Clinico, IDIBAPS, University of Barcelona @2 Barce-Iona @3 ESP @Z 14 aut.`
A14	`17`			`@1 Hôpital Saint-Louis @2 Paris @3 FRA @Z 13 aut.`
A14	`18`			`@1 University Hospital/U892 @2 Nantes @3 FRA @Z 34 aut.`
A14	`19`			`@1 University Feinberg Medical School @3 FRA @Z 15 aut.`
A14	`20`			`@1 Robert H. Lurie Comprehensive Cancer Center of Northwestern University @2 Chicago, IL @3 USA @Z 32 aut.`
A20				`@1 2598-2607`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20094 @5 354000189888660230`
A44				`@0 0000 @1 © 2011 INIST-CNRS. All rights reserved.`
A45				`@0 41 ref.`
A47	`01`	`1`		`@0 11-0307579`
A60				`@1 P @3 C`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of clinical oncology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Mycosis fungoides (MF) and Sezary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS.
C02	`01`	`X`		`@0 002B04`
C02	`02`	`X`		`@0 002B19B`
C03	`01`	`X`	`FRE`	`@0 Mycosis fongoïde @5 01`
C03	`01`	`X`	`ENG`	`@0 Mycosis fungoides @5 01`
C03	`01`	`X`	`SPA`	`@0 Micosis fungoides @5 01`
C03	`02`	`X`	`FRE`	`@0 Consensus @5 02`
C03	`02`	`X`	`ENG`	`@0 Consensus @5 02`
C03	`02`	`X`	`SPA`	`@0 Consenso @5 02`
C03	`03`	`X`	`FRE`	`@0 International @5 03`
C03	`03`	`X`	`ENG`	`@0 International @5 03`
C03	`03`	`X`	`SPA`	`@0 Internacional @5 03`
C03	`04`	`X`	`FRE`	`@0 Syndrome de Sezary @5 04`
C03	`04`	`X`	`ENG`	`@0 Sezary syndrome @5 04`
C03	`04`	`X`	`SPA`	`@0 Sezary síndrome @5 04`
C03	`05`	`X`	`FRE`	`@0 Peau @5 05`
C03	`05`	`X`	`ENG`	`@0 Skin @5 05`
C03	`05`	`X`	`SPA`	`@0 Piel @5 05`
C03	`06`	`X`	`FRE`	`@0 Etats-Unis @2 NG @5 06`
C03	`06`	`X`	`ENG`	`@0 United States @2 NG @5 06`
C03	`06`	`X`	`SPA`	`@0 Estados Unidos @2 NG @5 06`
C03	`07`	`X`	`FRE`	`@0 Cancer @2 NM @5 07`
C03	`07`	`X`	`ENG`	`@0 Cancer @2 NM @5 07`
C03	`07`	`X`	`SPA`	`@0 Cáncer @2 NM @5 07`
C03	`08`	`X`	`FRE`	`@0 Force @5 08`
C03	`08`	`X`	`ENG`	`@0 Force @5 08`
C03	`08`	`X`	`SPA`	`@0 Fuerza @5 08`
C03	`09`	`X`	`FRE`	`@0 Europe @2 NG @5 09`
C03	`09`	`X`	`ENG`	`@0 Europe @2 NG @5 09`
C03	`09`	`X`	`SPA`	`@0 Europa @2 NG @5 09`
C03	`10`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 10`
C03	`10`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 10`
C03	`10`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 10`
C03	`11`	`X`	`FRE`	`@0 Recherche @5 11`
C03	`11`	`X`	`ENG`	`@0 Research @5 11`
C03	`11`	`X`	`SPA`	`@0 Investigación @5 11`
C03	`12`	`X`	`FRE`	`@0 Traitement @5 12`
C03	`12`	`X`	`ENG`	`@0 Treatment @5 12`
C03	`12`	`X`	`SPA`	`@0 Tratamiento @5 12`
C03	`13`	`X`	`FRE`	`@0 Cancérologie @5 17`
C03	`13`	`X`	`ENG`	`@0 Cancerology @5 17`
C03	`13`	`X`	`SPA`	`@0 Cancerología @5 17`
C03	`14`	`X`	`FRE`	`@0 Chronique @5 25`
C03	`14`	`X`	`ENG`	`@0 Chronic @5 25`
C03	`14`	`X`	`SPA`	`@0 Crónico @5 25`
C03	`15`	`X`	`FRE`	`@0 Lymphome T cutané @4 CD @5 96`
C03	`15`	`X`	`ENG`	`@0 Cutaneous T cell lymphoma @4 CD @5 96`
C03	`16`	`X`	`FRE`	`@0 Hémopathie maligne lymphoïde @4 CD @5 97`
C03	`16`	`X`	`ENG`	`@0 Lymphoid neoplasm @4 CD @5 97`
C03	`17`	`X`	`FRE`	`@0 Hémopathie lymphoïde T @4 CD @5 98`
C03	`17`	`X`	`ENG`	`@0 T cell neoplasm @4 CD @5 98`
C07	`01`	`X`	`FRE`	`@0 Amérique du Nord @2 NG`
C07	`01`	`X`	`ENG`	`@0 North America @2 NG`
C07	`01`	`X`	`SPA`	`@0 America del norte @2 NG`
C07	`02`	`X`	`FRE`	`@0 Amérique @2 NG`
C07	`02`	`X`	`ENG`	`@0 America @2 NG`
C07	`02`	`X`	`SPA`	`@0 America @2 NG`
C07	`03`	`X`	`FRE`	`@0 Hémopathie maligne @2 NM @5 37`
C07	`03`	`X`	`ENG`	`@0 Malignant hemopathy @2 NM @5 37`
C07	`03`	`X`	`SPA`	`@0 Hemopatía maligna @2 NM @5 37`
C07	`04`	`X`	`FRE`	`@0 Pathologie de la peau @5 38`
C07	`04`	`X`	`ENG`	`@0 Skin disease @5 38`
C07	`04`	`X`	`SPA`	`@0 Piel patología @5 38`
C07	`05`	`X`	`FRE`	`@0 Hématodermie @5 39`
C07	`05`	`X`	`ENG`	`@0 Cutaneous hematologic disease @5 39`
C07	`05`	`X`	`SPA`	`@0 Hematodermia @5 39`
C07	`06`	`X`	`FRE`	`@0 Lymphome périphérique à cellules T @5 40`
C07	`06`	`X`	`ENG`	`@0 Peripheral T cell lymphoma @5 40`
C07	`06`	`X`	`SPA`	`@0 Linfoma célula T periférica @5 40`
C07	`07`	`X`	`FRE`	`@0 Lymphome non hodgkinien @5 41`
C07	`07`	`X`	`ENG`	`@0 Non Hodgkin lymphoma @5 41`
C07	`07`	`X`	`SPA`	`@0 Linfoma no Hodgkin @5 41`
C07	`08`	`X`	`FRE`	`@0 Syndrome lymphoprolifératif @2 NM @5 42`
C07	`08`	`X`	`ENG`	`@0 Lymphoproliferative syndrome @2 NM @5 42`
C07	`08`	`X`	`SPA`	`@0 Linfoproliferativo síndrome @2 NM @5 42`
N21				`@1 206`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B40

Links to Exploration step

Pascal:11-0307579

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer</title>
<author><name sortKey="Olsen, Elise A" sort="Olsen, Elise A" uniqKey="Olsen E" first="Elise A." last="Olsen">Elise A. Olsen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Whittaker, Sean" sort="Whittaker, Sean" uniqKey="Whittaker S" first="Sean" last="Whittaker">Sean Whittaker</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>St John's Institute of Dermatology, Guy's and St Thomas' National Health Services Foundation Trust, Kings College London</s1>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Kim, Youn H" sort="Kim, Youn H" uniqKey="Kim Y" first="Youn H." last="Kim">Youn H. Kim</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Stanford Cancer Center</s1>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Duvic, Madeleine" sort="Duvic, Madeleine" uniqKey="Duvic M" first="Madeleine" last="Duvic">Madeleine Duvic</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University of Texas MD Anderson Cancer Center</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Miles Prince, H" sort="Miles Prince, H" uniqKey="Miles Prince H" first="H." last="Miles Prince">H. Miles Prince</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Peter MacCallum Cancer Centre and University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Lessin, Stuart R" sort="Lessin, Stuart R" uniqKey="Lessin S" first="Stuart R." last="Lessin">Stuart R. Lessin</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Fox Chase Cancer Center</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Wood, Gary S" sort="Wood, Gary S" uniqKey="Wood G" first="Gary S." last="Wood">Gary S. Wood</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>University of Wisconsin and VA Medical Center</s1>
<s2>Madison, WI</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Willemze, Rein" sort="Willemze, Rein" uniqKey="Willemze R" first="Rein" last="Willemze">Rein Willemze</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>8 aut.</sZ>
<sZ>29 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Demierre, Marie France" sort="Demierre, Marie France" uniqKey="Demierre M" first="Marie-France" last="Demierre">Marie-France Demierre</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Boston University</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Pimpinelli, Nicola" sort="Pimpinelli, Nicola" uniqKey="Pimpinelli N" first="Nicola" last="Pimpinelli">Nicola Pimpinelli</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>University of Florence Medical School</s1>
<s2>Florence</s2>
<s3>ITA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Grazia Bernengo, Maria" sort="Grazia Bernengo, Maria" uniqKey="Grazia Bernengo M" first="Maria" last="Grazia Bernengo">Maria Grazia Bernengo</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Turin University</s1>
<s2>Turin</s2>
<s3>ITA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Ortiz Romero, Pablo L" sort="Ortiz Romero, Pablo L" uniqKey="Ortiz Romero P" first="Pablo L." last="Ortiz-Romero">Pablo L. Ortiz-Romero</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Universidad Complutense</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Bagot, Martine" sort="Bagot, Martine" uniqKey="Bagot M" first="Martine" last="Bagot">Martine Bagot</name>
<affiliation wicri:level="1"><inist:fA14 i1="17"><s1>Hôpital Saint-Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Estrach, Teresa" sort="Estrach, Teresa" uniqKey="Estrach T" first="Teresa" last="Estrach">Teresa Estrach</name>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Hospital Clinico, IDIBAPS, University of Barcelona</s1>
<s2>Barce-Iona</s2>
<s3>ESP</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Guitart, Joan" sort="Guitart, Joan" uniqKey="Guitart J" first="Joan" last="Guitart">Joan Guitart</name>
<affiliation wicri:level="1"><inist:fA14 i1="19"><s1>University Feinberg Medical School</s1>
<s3>FRA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Knobler, Robert" sort="Knobler, Robert" uniqKey="Knobler R" first="Robert" last="Knobler">Robert Knobler</name>
</author>
<author><name sortKey="Antonio Sanches, Jose" sort="Antonio Sanches, Jose" uniqKey="Antonio Sanches J" first="José" last="Antonio Sanches">José Antonio Sanches</name>
</author>
<author><name sortKey="Iwatsuki, Keiji" sort="Iwatsuki, Keiji" uniqKey="Iwatsuki K" first="Keiji" last="Iwatsuki">Keiji Iwatsuki</name>
</author>
<author><name sortKey="Sugaya, Makoto" sort="Sugaya, Makoto" uniqKey="Sugaya M" first="Makoto" last="Sugaya">Makoto Sugaya</name>
</author>
<author><name sortKey="Dummer, Reinhard" sort="Dummer, Reinhard" uniqKey="Dummer R" first="Reinhard" last="Dummer">Reinhard Dummer</name>
</author>
<author><name sortKey="Pittelkow, Mark" sort="Pittelkow, Mark" uniqKey="Pittelkow M" first="Mark" last="Pittelkow">Mark Pittelkow</name>
</author>
<author><name sortKey="Hoppe, Richard" sort="Hoppe, Richard" uniqKey="Hoppe R" first="Richard" last="Hoppe">Richard Hoppe</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Stanford University</s1>
<s2>Stanford</s2>
<s3>USA</s3>
<sZ>22 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Parker, Sareeta" sort="Parker, Sareeta" uniqKey="Parker S" first="Sareeta" last="Parker">Sareeta Parker</name>
</author>
<author><name sortKey="Geskin, Larisa" sort="Geskin, Larisa" uniqKey="Geskin L" first="Larisa" last="Geskin">Larisa Geskin</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>24 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Pinter Brown, Lauren" sort="Pinter Brown, Lauren" uniqKey="Pinter Brown L" first="Lauren" last="Pinter-Brown">Lauren Pinter-Brown</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>University of California at Los Angeles</s1>
<s2>Los Angeles, CA</s2>
<s3>USA</s3>
<sZ>25 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Girardi, Michael" sort="Girardi, Michael" uniqKey="Girardi M" first="Michael" last="Girardi">Michael Girardi</name>
</author>
<author><name sortKey="Burg, Gunter" sort="Burg, Gunter" uniqKey="Burg G" first="Günter" last="Burg">Günter Burg</name>
</author>
<author><name sortKey="Ranki, Annamari" sort="Ranki, Annamari" uniqKey="Ranki A" first="Annamari" last="Ranki">Annamari Ranki</name>
</author>
<author><name sortKey="Vermeer, Maartan" sort="Vermeer, Maartan" uniqKey="Vermeer M" first="Maartan" last="Vermeer">Maartan Vermeer</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>8 aut.</sZ>
<sZ>29 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Horwitz, Steven" sort="Horwitz, Steven" uniqKey="Horwitz S" first="Steven" last="Horwitz">Steven Horwitz</name>
</author>
<author><name sortKey="Heald, Peter" sort="Heald, Peter" uniqKey="Heald P" first="Peter" last="Heald">Peter Heald</name>
</author>
<author><name sortKey="Rosen, Steve" sort="Rosen, Steve" uniqKey="Rosen S" first="Steve" last="Rosen">Steve Rosen</name>
<affiliation wicri:level="1"><inist:fA14 i1="20"><s1>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>32 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Cerroni, Lorenzo" sort="Cerroni, Lorenzo" uniqKey="Cerroni L" first="Lorenzo" last="Cerroni">Lorenzo Cerroni</name>
</author>
<author><name sortKey="Dreno, Brigette" sort="Dreno, Brigette" uniqKey="Dreno B" first="Brigette" last="Dreno">Brigette Dreno</name>
<affiliation wicri:level="1"><inist:fA14 i1="18"><s1>University Hospital/U892</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>34 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Vonderheid, Eric C" sort="Vonderheid, Eric C" uniqKey="Vonderheid E" first="Eric C." last="Vonderheid">Eric C. Vonderheid</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0307579</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0307579 INIST</idno>
<idno type="RBID">Pascal:11-0307579</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001B40</idno>
<idno type="wicri:Area/PascalFrancis/Curation">004404</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer</title>
<author><name sortKey="Olsen, Elise A" sort="Olsen, Elise A" uniqKey="Olsen E" first="Elise A." last="Olsen">Elise A. Olsen</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Whittaker, Sean" sort="Whittaker, Sean" uniqKey="Whittaker S" first="Sean" last="Whittaker">Sean Whittaker</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>St John's Institute of Dermatology, Guy's and St Thomas' National Health Services Foundation Trust, Kings College London</s1>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Kim, Youn H" sort="Kim, Youn H" uniqKey="Kim Y" first="Youn H." last="Kim">Youn H. Kim</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Stanford Cancer Center</s1>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Duvic, Madeleine" sort="Duvic, Madeleine" uniqKey="Duvic M" first="Madeleine" last="Duvic">Madeleine Duvic</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>University of Texas MD Anderson Cancer Center</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Miles Prince, H" sort="Miles Prince, H" uniqKey="Miles Prince H" first="H." last="Miles Prince">H. Miles Prince</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Peter MacCallum Cancer Centre and University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Lessin, Stuart R" sort="Lessin, Stuart R" uniqKey="Lessin S" first="Stuart R." last="Lessin">Stuart R. Lessin</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Fox Chase Cancer Center</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Wood, Gary S" sort="Wood, Gary S" uniqKey="Wood G" first="Gary S." last="Wood">Gary S. Wood</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>University of Wisconsin and VA Medical Center</s1>
<s2>Madison, WI</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Willemze, Rein" sort="Willemze, Rein" uniqKey="Willemze R" first="Rein" last="Willemze">Rein Willemze</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>8 aut.</sZ>
<sZ>29 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Demierre, Marie France" sort="Demierre, Marie France" uniqKey="Demierre M" first="Marie-France" last="Demierre">Marie-France Demierre</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Boston University</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Pimpinelli, Nicola" sort="Pimpinelli, Nicola" uniqKey="Pimpinelli N" first="Nicola" last="Pimpinelli">Nicola Pimpinelli</name>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>University of Florence Medical School</s1>
<s2>Florence</s2>
<s3>ITA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Grazia Bernengo, Maria" sort="Grazia Bernengo, Maria" uniqKey="Grazia Bernengo M" first="Maria" last="Grazia Bernengo">Maria Grazia Bernengo</name>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Turin University</s1>
<s2>Turin</s2>
<s3>ITA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Ortiz Romero, Pablo L" sort="Ortiz Romero, Pablo L" uniqKey="Ortiz Romero P" first="Pablo L." last="Ortiz-Romero">Pablo L. Ortiz-Romero</name>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Universidad Complutense</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Bagot, Martine" sort="Bagot, Martine" uniqKey="Bagot M" first="Martine" last="Bagot">Martine Bagot</name>
<affiliation wicri:level="1"><inist:fA14 i1="17"><s1>Hôpital Saint-Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Estrach, Teresa" sort="Estrach, Teresa" uniqKey="Estrach T" first="Teresa" last="Estrach">Teresa Estrach</name>
<affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Hospital Clinico, IDIBAPS, University of Barcelona</s1>
<s2>Barce-Iona</s2>
<s3>ESP</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Guitart, Joan" sort="Guitart, Joan" uniqKey="Guitart J" first="Joan" last="Guitart">Joan Guitart</name>
<affiliation wicri:level="1"><inist:fA14 i1="19"><s1>University Feinberg Medical School</s1>
<s3>FRA</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Knobler, Robert" sort="Knobler, Robert" uniqKey="Knobler R" first="Robert" last="Knobler">Robert Knobler</name>
</author>
<author><name sortKey="Antonio Sanches, Jose" sort="Antonio Sanches, Jose" uniqKey="Antonio Sanches J" first="José" last="Antonio Sanches">José Antonio Sanches</name>
</author>
<author><name sortKey="Iwatsuki, Keiji" sort="Iwatsuki, Keiji" uniqKey="Iwatsuki K" first="Keiji" last="Iwatsuki">Keiji Iwatsuki</name>
</author>
<author><name sortKey="Sugaya, Makoto" sort="Sugaya, Makoto" uniqKey="Sugaya M" first="Makoto" last="Sugaya">Makoto Sugaya</name>
</author>
<author><name sortKey="Dummer, Reinhard" sort="Dummer, Reinhard" uniqKey="Dummer R" first="Reinhard" last="Dummer">Reinhard Dummer</name>
</author>
<author><name sortKey="Pittelkow, Mark" sort="Pittelkow, Mark" uniqKey="Pittelkow M" first="Mark" last="Pittelkow">Mark Pittelkow</name>
</author>
<author><name sortKey="Hoppe, Richard" sort="Hoppe, Richard" uniqKey="Hoppe R" first="Richard" last="Hoppe">Richard Hoppe</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Stanford University</s1>
<s2>Stanford</s2>
<s3>USA</s3>
<sZ>22 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Parker, Sareeta" sort="Parker, Sareeta" uniqKey="Parker S" first="Sareeta" last="Parker">Sareeta Parker</name>
</author>
<author><name sortKey="Geskin, Larisa" sort="Geskin, Larisa" uniqKey="Geskin L" first="Larisa" last="Geskin">Larisa Geskin</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>24 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Pinter Brown, Lauren" sort="Pinter Brown, Lauren" uniqKey="Pinter Brown L" first="Lauren" last="Pinter-Brown">Lauren Pinter-Brown</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>University of California at Los Angeles</s1>
<s2>Los Angeles, CA</s2>
<s3>USA</s3>
<sZ>25 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Girardi, Michael" sort="Girardi, Michael" uniqKey="Girardi M" first="Michael" last="Girardi">Michael Girardi</name>
</author>
<author><name sortKey="Burg, Gunter" sort="Burg, Gunter" uniqKey="Burg G" first="Günter" last="Burg">Günter Burg</name>
</author>
<author><name sortKey="Ranki, Annamari" sort="Ranki, Annamari" uniqKey="Ranki A" first="Annamari" last="Ranki">Annamari Ranki</name>
</author>
<author><name sortKey="Vermeer, Maartan" sort="Vermeer, Maartan" uniqKey="Vermeer M" first="Maartan" last="Vermeer">Maartan Vermeer</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>8 aut.</sZ>
<sZ>29 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author><name sortKey="Horwitz, Steven" sort="Horwitz, Steven" uniqKey="Horwitz S" first="Steven" last="Horwitz">Steven Horwitz</name>
</author>
<author><name sortKey="Heald, Peter" sort="Heald, Peter" uniqKey="Heald P" first="Peter" last="Heald">Peter Heald</name>
</author>
<author><name sortKey="Rosen, Steve" sort="Rosen, Steve" uniqKey="Rosen S" first="Steve" last="Rosen">Steve Rosen</name>
<affiliation wicri:level="1"><inist:fA14 i1="20"><s1>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>32 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Cerroni, Lorenzo" sort="Cerroni, Lorenzo" uniqKey="Cerroni L" first="Lorenzo" last="Cerroni">Lorenzo Cerroni</name>
</author>
<author><name sortKey="Dreno, Brigette" sort="Dreno, Brigette" uniqKey="Dreno B" first="Brigette" last="Dreno">Brigette Dreno</name>
<affiliation wicri:level="1"><inist:fA14 i1="18"><s1>University Hospital/U892</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>34 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Vonderheid, Eric C" sort="Vonderheid, Eric C" uniqKey="Vonderheid E" first="Eric C." last="Vonderheid">Eric C. Vonderheid</name>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cancer</term>
<term>Cancerology</term>
<term>Chronic</term>
<term>Consensus</term>
<term>Cutaneous T cell lymphoma</term>
<term>Europe</term>
<term>Force</term>
<term>International</term>
<term>Lymphoid neoplasm</term>
<term>Malignant tumor</term>
<term>Mycosis fungoides</term>
<term>Research</term>
<term>Sezary syndrome</term>
<term>Skin</term>
<term>T cell neoplasm</term>
<term>Treatment</term>
<term>United States</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Mycosis fongoïde</term>
<term>Consensus</term>
<term>International</term>
<term>Syndrome de Sezary</term>
<term>Peau</term>
<term>Etats-Unis</term>
<term>Cancer</term>
<term>Force</term>
<term>Europe</term>
<term>Tumeur maligne</term>
<term>Recherche</term>
<term>Traitement</term>
<term>Cancérologie</term>
<term>Chronique</term>
<term>Lymphome T cutané</term>
<term>Hémopathie maligne lymphoïde</term>
<term>Hémopathie lymphoïde T</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Cancer</term>
<term>Recherche</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Mycosis fungoides (MF) and Sezary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0732-183X</s0>
</fA01>
<fA03 i2="1"><s0>J. clin. oncol.</s0>
</fA03>
<fA05><s2>29</s2>
</fA05>
<fA06><s2>18</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>OLSEN (Elise A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>WHITTAKER (Sean)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KIM (Youn H.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DUVIC (Madeleine)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MILES PRINCE (H.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>LESSIN (Stuart R.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>WOOD (Gary S.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>WILLEMZE (Rein)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>DEMIERRE (Marie-France)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>PIMPINELLI (Nicola)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>GRAZIA BERNENGO (Maria)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>ORTIZ-ROMERO (Pablo L.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>BAGOT (Martine)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>ESTRACH (Teresa)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>GUITART (Joan)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>KNOBLER (Robert)</s1>
</fA11>
<fA11 i1="17" i2="1"><s1>ANTONIO SANCHES (José)</s1>
</fA11>
<fA11 i1="18" i2="1"><s1>IWATSUKI (Keiji)</s1>
</fA11>
<fA11 i1="19" i2="1"><s1>SUGAYA (Makoto)</s1>
</fA11>
<fA11 i1="20" i2="1"><s1>DUMMER (Reinhard)</s1>
</fA11>
<fA11 i1="21" i2="1"><s1>PITTELKOW (Mark)</s1>
</fA11>
<fA11 i1="22" i2="1"><s1>HOPPE (Richard)</s1>
</fA11>
<fA11 i1="23" i2="1"><s1>PARKER (Sareeta)</s1>
</fA11>
<fA11 i1="24" i2="1"><s1>GESKIN (Larisa)</s1>
</fA11>
<fA11 i1="25" i2="1"><s1>PINTER-BROWN (Lauren)</s1>
</fA11>
<fA11 i1="26" i2="1"><s1>GIRARDI (Michael)</s1>
</fA11>
<fA11 i1="27" i2="1"><s1>BURG (Günter)</s1>
</fA11>
<fA11 i1="28" i2="1"><s1>RANKI (Annamari)</s1>
</fA11>
<fA11 i1="29" i2="1"><s1>VERMEER (Maartan)</s1>
</fA11>
<fA11 i1="30" i2="1"><s1>HORWITZ (Steven)</s1>
</fA11>
<fA11 i1="31" i2="1"><s1>HEALD (Peter)</s1>
</fA11>
<fA11 i1="32" i2="1"><s1>ROSEN (Steve)</s1>
</fA11>
<fA11 i1="33" i2="1"><s1>CERRONI (Lorenzo)</s1>
</fA11>
<fA11 i1="34" i2="1"><s1>DRENO (Brigette)</s1>
</fA11>
<fA11 i1="35" i2="1"><s1>VONDERHEID (Eric C.)</s1>
</fA11>
<fA14 i1="01"><s1>Duke University Medical Center</s1>
<s2>Durham, NC</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>St John's Institute of Dermatology, Guy's and St Thomas' National Health Services Foundation Trust, Kings College London</s1>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Stanford Cancer Center</s1>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Stanford University</s1>
<s2>Stanford</s2>
<s3>USA</s3>
<sZ>22 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>University of California at Los Angeles</s1>
<s2>Los Angeles, CA</s2>
<s3>USA</s3>
<sZ>25 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>University of Texas MD Anderson Cancer Center</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Peter MacCallum Cancer Centre and University of Melbourne</s1>
<s2>Melbourne</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Fox Chase Cancer Center</s1>
<s2>Philadelphia</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>24 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>University of Wisconsin and VA Medical Center</s1>
<s2>Madison, WI</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>8 aut.</sZ>
<sZ>29 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Boston University</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>University of Florence Medical School</s1>
<s2>Florence</s2>
<s3>ITA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Turin University</s1>
<s2>Turin</s2>
<s3>ITA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="15"><s1>Universidad Complutense</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="16"><s1>Hospital Clinico, IDIBAPS, University of Barcelona</s1>
<s2>Barce-Iona</s2>
<s3>ESP</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="17"><s1>Hôpital Saint-Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="18"><s1>University Hospital/U892</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>34 aut.</sZ>
</fA14>
<fA14 i1="19"><s1>University Feinberg Medical School</s1>
<s3>FRA</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="20"><s1>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>32 aut.</sZ>
</fA14>
<fA20><s1>2598-2607</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20094</s2>
<s5>354000189888660230</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>41 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0307579</s0>
</fA47>
<fA60><s1>P</s1>
<s3>C</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of clinical oncology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Mycosis fungoides (MF) and Sezary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B19B</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Mycosis fongoïde</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Mycosis fungoides</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Micosis fungoides</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Consensus</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Consensus</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Consenso</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>International</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>International</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Internacional</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Syndrome de Sezary</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Sezary syndrome</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Sezary síndrome</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Peau</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Skin</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Piel</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Etats-Unis</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>United States</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Estados Unidos</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Force</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Force</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Fuerza</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Europe</s0>
<s2>NG</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Europe</s0>
<s2>NG</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Europa</s0>
<s2>NG</s2>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Recherche</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Research</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Investigación</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Traitement</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Treatment</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Cancérologie</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Cancerology</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Cancerología</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Chronique</s0>
<s5>25</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Chronic</s0>
<s5>25</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Crónico</s0>
<s5>25</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Lymphome T cutané</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Cutaneous T cell lymphoma</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Hémopathie maligne lymphoïde</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Lymphoid neoplasm</s0>
<s4>CD</s4>
<s5>97</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Hémopathie lymphoïde T</s0>
<s4>CD</s4>
<s5>98</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>T cell neoplasm</s0>
<s4>CD</s4>
<s5>98</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Amérique du Nord</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>North America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>America del norte</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Amérique</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>America</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Hémopathie maligne</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Malignant hemopathy</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Hemopatía maligna</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de la peau</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Skin disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Piel patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Hématodermie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Cutaneous hematologic disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Hematodermia</s0>
<s5>39</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Lymphome périphérique à cellules T</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Peripheral T cell lymphoma</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Linfoma célula T periférica</s0>
<s5>40</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Lymphome non hodgkinien</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Non Hodgkin lymphoma</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Linfoma no Hodgkin</s0>
<s5>41</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Syndrome lymphoprolifératif</s0>
<s2>NM</s2>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Lymphoproliferative syndrome</s0>
<s2>NM</s2>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Linfoproliferativo síndrome</s0>
<s2>NM</s2>
<s5>42</s5>
</fC07>
<fN21><s1>206</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004404 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 004404 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:11-0307579
   |texte=   Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie